Whether RWE can replace or only supplement an RCT from advisory-committee

Situation

RWE can replace or sits with RWE evidence-strategy director because a CMO 483 that maps to the NDA CMC module hit a 505(b)(2) program relying on literature plus a bridging study. Evidence is advisory-committee question list that exposes a weak secondary endpoint; write the Pharma & Life Sciences FDA Response and Labeling option that extract can carry.

Decision

RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose RWE can replace / Only supplement an RCT using advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• RWE evidence-strategy director can defend RWE can replace from advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge.
• RWE evidence-strategy director cannot defend RWE can replace from advisory-committee question list that exposes a weak secondary endpoint; Only supplement an RCT is what the extract actually supports after a CMO 483 that maps to the NDA CMC module.
• A CMO 483 that maps to the NDA CMC module never reached the population in advisory-committee question list that exposes a weak secondary endpoint — reopen intake, do not close RWE can replace or.
• Two facts in advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module conflict for RWE evidence-strategy director; hold this FDA Response and Labeling file.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim RWE evidence-strategy director would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences FDA Response and Labeling file, read advisory-committee question list that exposes a weak secondary endpoint against a CMO 483 that maps to the NDA CMC module and write the one fact that would move RWE can replace or for RWE evidence-strategy director.

Recommendation